HPV16 mutant E6/E7 construct is protective in mouse model
So, according to the findings, the recombinant protein could induce stronger protection compared to the DNA vaccine form. Protein/Protein and DNA/Protein are promising administration strategies for presenting this construct to develop an HPV-16 therapeutic vaccine candidate.
Authors
- Ghasem Mosayebi (ORCID: https://orcid.org/0000-0003-3877-0783)
- Samira Sadelaji (ORCID: https://orcid.org/0000-0002-0376-9822)
- Ali Ganji (ORCID: https://orcid.org/0000-0002-2632-9889)
- Saeid Babaei (ORCID: https://orcid.org/0000-0002-7990-6854)
- Ehsan Raoufi (ORCID: https://orcid.org/0000-0002-8502-9106)
- Maryam Moazami Goodarzi (ORCID: https://orcid.org/0000-0002-8451-0512)
- Hamid Abtahi (ORCID: https://orcid.org/0000-0003-3270-4304)
Institutions
- Arak University of Medical Sciences (IR)
- Iran University of Medical Sciences (IR)
Publication Details
- Journal
- BMC Biotechnology
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1186/s12896-024-00893-y
- Citations
- 1
- Primary Topic
- vaccines and immunoinformatics approaches
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Arak University of Medical Sciences